A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis
Completed · Phase 2 · NCT03544229
Conditions: Diabetic Gastroparesis, Idiopathic Gastroparesis
At a glance
- Research payments reported, 2025
- $750
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 242
About the trial
- Sponsor
- Millennium Pharmaceuticals, Inc.
- Tested
- TAK-906 Maleate (drug), Placebo (drug)
- Dates
- Started 2018-10-14; completion 2021-07-15
- Results posted
- Yes
The purpose of this study is to assess the efficacy and safety of treatment with 2 dose levels of TAK-906 in adult participants with gastroparesis compared with placebo during 12 weeks of treatment.
From ClinicalTrials.gov, last updated 2022-11-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Takeda Pharmaceuticals U.S.A., Inc. reported $750 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Quality Medical Research PLLC $750
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.